Form 8-K

8-K — Jasper Therapeutics, Inc.

Accession: 0001213900-26-090055

Filed: 2026-08-14

Period: 2026-08-14

CIK: 0001788028

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0302049-8k_jasper.htm (Primary)

EX-99.1 — PRESS RELEASE, DATED AUGUST 14, 2026 (ea030204901ex99-1.htm)

GRAPHIC (ea030204901_ex99-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0302049-8k_jasper.htm · Sequence: 1

false

0001788028

2026-08-14

0001788028

JSPR:VotingCommonStockParValue0.0001PerShareMember

2026-08-14

0001788028

JSPR:RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

2026-08-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):

August 14, 2026

JASPER THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in its

Charter)

Delaware

001-39138

84-2984849

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

2200 Bridge Pkwy Suite #102

Redwood City, California 94065

(Address of Principal Executive Offices) (Zip

Code)

(650) 549-1400

Registrant’s telephone number, including

area code

N/A

(Former Name, or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act:

(Title of each class)

(Trading Symbol)

(Name of exchange on which registered)

Voting Common Stock, par value $0.0001 per share

JSPR

The Nasdaq Stock Market LLC

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

JSPRW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2026, Jasper Therapeutics, Inc.

issued a press release reporting its financial results for the quarter ended June 30, 2026 and providing a corporate update. A copy of

the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instructions B.2 of

Form 8-K, the information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished under Item

2.02 and Item 9.01 of Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not

be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be

expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release, dated August 14, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2026

JASPER THERAPEUTICS, INC.

By:

/s/ Herb Cross

Name:

Herb Cross

Title:

Chief Financial Officer

EX-99.1 — PRESS RELEASE, DATED AUGUST 14, 2026

EX-99.1

Filename: ea030204901ex99-1.htm · Sequence: 2

Exhibit 99.1

Jasper Therapeutics Reports Second Quarter 2026

Financial Results and Provides Corporate Update

Acquisition of Kira Pharmaceuticals closed in

July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

Completed a concurrent PIPE financing raising

$132 million in gross proceeds

REDWOOD CITY, Calif., August 14, 2026 (GLOBE

NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused

on the design and development of innovative therapies to treat immune-mediated diseases, today reported results for the fiscal quarter

ended June 30, 2026, and provided a corporate update.

“We are excited

to unite Jasper Therapeutics and Kira Pharmaceuticals to advance our shared mission of developing a differentiated portfolio of innovative

therapies for patients with significant immune-mediated diseases. Supported by our recent $132 million financing led by leading life

sciences investors, we believe that we have sufficient capital to fund planned operations through the second half of 2028. We plan to

advance development of our lead asset KP-104, a novel dual inhibitor of the complement cascade, in multiple indications, progress briquilimab

towards a potential BLA, and to commence first in human studies for KP-701,” said Jeet Mahal, President and Chief Executive

Officer of Jasper. “The combined company now has access to significant resources in the United States and China, which we believe

will allow us to rapidly advance our portfolio across multiple diseases of unmet need.”

Corporate Updates for Second Quarter 2026 and Recent Weeks

● On

July 16, 2026, Jasper completed the acquisition of Kira Pharmaceuticals (“Kira”), a former Cayman limited company that was

engaged in the design of complement therapies to treat immune-mediated diseases, in an all-stock transaction.

● Concurrently

with the acquisition, Jasper entered into a securities purchase agreement for the sale of non-voting convertible preferred stock (the

“Preferred Stock”) in a private placement co-led by Affinity Asset Advisors, LLC and Ikarian Capital LLC with participation

from other leading life science investors. The private placement resulted in total gross proceeds of approximately $132 million.

● The

combined company is focused on advancing its consolidated pipeline of potential best-in-class innovative therapies for immunologically-driven

disorders, including:

o KP-104 (Vensobafusp alfa), a Phase 2/3 ready, potentially best-in-disease, bifunctional biologic targeting

both the alternative and terminal pathways within the complement cascade for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)

and high unmet need nephrology disorders. KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and

interim data from Stage 1 of the trial is expected in the fourth quarter of 2026. Based on previous, positive results in treatment-naïve

PNH, the combined company is also planning for an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to

announce next steps for development in PNH in the first half of 2027;

o Briquilimab, a late-stage, potentially best-in-class anti-KIT antibody with broad therapeutic utility across multiple transplant and

immunologic indications. Based on positive, long-term data generated in SCID, the combined company is progressing its efforts towards

a pre-BLA meeting with the FDA and expects to announce next steps in the first quarter of 2027; and

o KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The combined company

expects to file a clinical trial application (CTA) and/or an investigational new drug (IND) for Phase 1 evaluation in the first quarter

of 2027.

Second Quarter Fiscal 2026 Financial Results

● Cash

and cash equivalents as of June 30, 2026, totaled $7.3 million.

● Research

and development expense for the three months ended June 30, 2026, was $5.1 million.

● General

and administrative expense for the three months ended June 30, 2026, was $4.1 million.

● Jasper

reported a net loss of $2.8 million, or basic and diluted net loss per share attributable to common stockholders of $0.10 for the three

months ended June 30, 2026.

About Jasper

The combined company is a clinical stage biotechnology

company focused on the design and development of innovative therapies to treat immune-mediated diseases. The combined company is advancing

a pipeline of medicines including KP-104, briquilimab, and KP-701. KP-104 is a potential best-in-class dual-complement inhibitor that

has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other high unmet need nephrology

disorders. Briquilimab is an anti-KIT antibody which has demonstrated positive clinical results both as a conditioning agent for stem

cell transplant and mast cell mediated diseases such as chronic urticarias and allergic asthma. KP-701, a novel, dual-acting anti-CD79BxCD32B

monoclonal antibody (mAb) for autoantibody-mediated disorders currently advancing to the clinic.

Forward-Looking Statements

Certain statements contained in this press release are or may be considered

“forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified

by the fact that they do not relate strictly to historic or current facts. They use words such as “estimate,” “expect,”

“intend,” “believe,” “plan,” “anticipate,” “potential,” “projected”

and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition.

Jasper cautions that these statements are based upon the current beliefs and expectations of Jasper’s management and are subject

to significant risks, uncertainties and assumptions, including, without limitation, risks related to the market price of Jasper’s

common stock relative to the value suggested by the exchange ratio in connection with the merger; unexpected costs, charges or expenses

resulting from the merger; potential adverse reactions or changes to business relationships resulting from the announcement or completion

of the merger; the uncertainties associated with the Combined Company’s product candidates, as well as risks associated with the

clinical development and regulatory approval of product candidates, including potential delays in the commencement, enrollment and completion

of clinical trials; risks related to the inability of the Combined Company to obtain sufficient additional capital to continue to advance

product candidates and its preclinical programs; uncertainties in obtaining successful clinical results for product candidates and unexpected

costs that may result therefrom; risks related to the failure to realize any value from product candidates and preclinical programs being

developed and anticipated to be developed in light of inherent risks and difficulties involved in successfully bringing product candidates

to market; risks associated with the possible failure to realize certain anticipated benefits of the merger, including with respect to

future financial and operating results; risks related to the integration of Kira and realization of anticipated benefits from the combination;

the possibility that holders of CVRs may never receive any proceeds; risks related to the possibility that Jasper’s shareholders

may not approve the conversion of the Preferred Stock and the consequences if such approval is not obtained, and such additional risks

and uncertainties contained in the “Risk Factors” section of Jasper’s Annual Reports on Form 10-K for the year ended

December 31, 2025, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that Jasper has subsequently filed or may subsequently

file with the SEC. Statements regarding future actions, future performance and/or future results including, without limitation, those

relating to the timing for completion, and results of, scheduled or additional clinical trials and the FDA’s or other regulatory

review and/or approval and commercial launch and sales results (if any) of the Combined Company’s formulations and product candidates

and regulatory filings related to the same, financial projections and targets, including, without limitation, cash runway, operating plans,

future capital requirements and the sufficiency of existing cash resources, business strategy, plans and objectives for future operations,

statements regarding the Combined Company and its operations and prospects, may not occur, and actual results could differ materially

and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions,

the forward-looking events and circumstances discussed in this press release are inherently uncertain and may not occur, and actual results

could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not

rely upon forward-looking statements as predictions of future events. There is no obligation to update publicly or revise any forward-looking

statements for any reason after the date of this press release or to conform these statements to actual results or to changes in the Combined

Company’s expectations, whether as a result of new information, future events, inaccuracies that become apparent after the date

hereof or otherwise, except as may be required under applicable securities laws.

Contacts:

Alex Gray (investors)

Jasper Therapeutics

650-549-1454

agray@jaspertx.com

Argot Partners (investors and media)

kira@argotpartners.com

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS

OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share

and per share data)

(unaudited)

Three Months Ended

June 30, 2026

Six Months Ended

June 30,

2026

2025

2026

2025

Operating expenses

Research and development(1)

$ 5,135

$ 21,196

$ 10,949

$ 37,353

General and administrative(1)

4,072

5,880

9,210

11,525

Total operating expenses

9,207

27,076

20,159

48,878

Loss from operations

(9,207 )

(27,076 )

(20,159 )

(48,878 )

Interest income

437

246

1,061

Change in fair value of warrant liability

3,980

—

13,620

—

Other income (expense), net

2,385

(84 )

2,359

(147 )

Total other income, net

6,447

353

16,225

914

Net loss and comprehensive loss

$ (2,760 )

$ (26,723 )

$ (3,934 )

$ (47,964 )

Net loss per share attributable to common stockholders, basic and diluted

$ (0.10 )

$ (1.74 )

$ (0.14 )

$ (3.16 )

Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted

28,696,937

15,333,962

28,684,447

15,178,904

(1) Amounts include non-cash stock based compensation expense as

follows (in thousands):

Three Months Ended

June 30, 2026

Six Months Ended

June 30,

2026

2025

2026

2025

Research and development

$ 185

$ 543

$ 406

$ 1,114

General and administrative

579

1,274

781

2,514

Total

$ 764

$ 1,817

$ 1,187

$ 3,628

JASPER THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

(unaudited)

June 30,

2026

December 31,

2025

Assets

Current assets:

Cash and cash equivalents

$ 7,314

$ 28,692

Restricted cash, current

417

Prepaid expenses and other current assets

3,840

5,953

Total current assets

11,571

34,645

Property and equipment, net

102

Operating lease right-of-use assets

128

502

Restricted cash, non-current

417

Other non-current assets

113

Total assets

$ 11,802

$ 35,779

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$ 2,778

$ 6,220

Current portion of operating lease liabilities

270

1,235

Accrued expenses and other current liabilities

4,797

5,745

Total current liabilities

7,845

13,200

Warrant liability

2,544

16,164

Other non-current liabilities

2,264

Total liabilities

10,389

31,628

Stockholders’ equity:

—

Preferred stock

Common stock

Additional paid-in capital

322,014

320,818

Accumulated deficit

(320,604 )

(316,670 )

Total stockholders’ equity

1,413

4,151

Total liabilities and stockholders’ equity

$ 11,802

$ 35,779

GRAPHIC

Filename: ea030204901_ex99-1img1.jpg · Sequence: 3

Binary file (22905 bytes)

Download ea030204901_ex99-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 14, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 14, 2026

Entity File Number

001-39138

Entity Registrant Name

JASPER THERAPEUTICS, INC.

Entity Central Index Key

0001788028

Entity Tax Identification Number

84-2984849

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2200 Bridge Pkwy Suite #102

Entity Address, City or Town

Redwood City

Entity Address, State or Province

Entity Address, Postal Zip Code

94065

City Area Code

650

Local Phone Number

549-1400

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Voting Common Stock, par value $0.0001 per share

Title of 12(b) Security

Voting Common Stock, par value $0.0001 per share

Trading Symbol

JSPR

Security Exchange Name

NASDAQ

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Title of 12(b) Security

Redeemable Warrants, each ten warrants exercisable for one share of Voting Common Stock at an exercise price of $115.00

Trading Symbol

JSPRW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_VotingCommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=JSPR_RedeemableWarrantsEachTenWarrantsExercisableForOneShareOfVotingCommonStockAtExercisePriceOf115.00Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: